Macrocure Ltd. (MCUR) was a biotechnology company that developed advanced wound care products based on its proprietary healing technology platform, CureXcell. The platform was designed to stimulate and accelerate the natural healing process of chronic and other hard-to-heal wounds.
Macrocure's flagship product, CureXcell, was a unique biological substance made up of white blood cells, growth factors, and other natural healing agents. The product was designed to be administered topically to the wound site, where it could help to stimulate the body's own healing processes.
The company's primary focus was on the development and commercialization of CureXcell for the treatment of diabetic foot ulcers, venous leg ulcers, and pressure ulcers. The company also conducted research into potential applications of its technology in other areas, including surgical wound healing and tissue repair.
However, in 2017, Macrocure announced that it was winding down operations and liquidating its assets. The company cited a lack of funding as the reason for its decision, as well as the inability to find a strategic partner to help advance the development and commercialization of CureXcell.
Investors in MCUR should be aware of the risks associated with investing in biotechnology companies, which are subject to significant regulatory and clinical trial risks. Additionally, the winding down of operations and liquidation of assets means that MCUR is no longer an active publicly traded company, and its shares have no value.
In summary, Macrocure Ltd. was a biotechnology company that developed advanced wound care products based on its proprietary healing technology platform, CureXcell. The company announced its decision to wind down operations and liquidate its assets in 2017 due to a lack of funding and the inability to find a strategic partner. Investors should be aware of the risks associated with investing in biotechnology companies and the fact that MCUR is no longer an active publicly traded company.
|
